Drug Profile
Dexamethasone sodium phosphate Visulex - Aciont
Alternative Names: Dexamethasone sodium phosphate - Visulex®; DSP-Visulex®Latest Information Update: 14 Jan 2022
Price :
$50
*
At a glance
- Originator Aciont
- Class Anti-inflammatories; Antiallergics; Antiemetics; Antihyperglycaemics; Antineoplastics; Antirheumatics; Eye disorder therapies; Fluorinated steroids; Glucocorticoids; Ketones; Non-opioid analgesics; Phosphates; Pregnadienetriols; Small molecules; Sodium compounds; Vestibular disorder therapies
- Mechanism of Action Glucocorticoid receptor agonists; Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase I/II Uveitis
Most Recent Events
- 11 Oct 2019 Aciont has patent protection for Visulex ocular drug delivery system in USA
- 05 Apr 2017 Phase-I/II development for Uveitis is ongoing in USA (Ophthalmic,Controlled release) (NCT02309385)
- 03 Mar 2017 Aciont completes a phase I/II trial for Uveitis in USA (Ophthalmic, Controlled release) (NCT02309385)